Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

 Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

Lilly Collaborates with Biolojic to Discover and Develop Antibody Therapies for Diabetes

Shots:

  • Biolojic to receive ~$121M including development and commercialization milestones and a promissory note that may be convertible into Biolojic equity in future
  • Additionally, Biolojic is eligible to receive royalties on sales of therapies that emerges during the collaboration
  • The collaboration will leverage Biolojic’s AI-based multibody platform to discover and develop a potential novel Ab-based therapy for diabetes

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: US News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post